Roche Holding Ltd · SIX:RO
Roche — Kepler Cheuvreux Virtual CEO/CFO Tour 2024
20 slides from Roche's conference presentation, Dec 3, 2024
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Opening remarks
Opening remarks Alan Hippe | CFO Roche Group Kepler Cheuvreux Virtual CEO/CFO Tour 3 December 2024
Slide 4: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 5: YTD Sep 2024: Strong growth in both divisions
YTD Sep 2024: Strong growth in both divisions Q3 without significant COVID-19 impact Pharma* Diagnostics* Quarterly sales evolution 2022-2024 Quarterly sales evolution 2022-2024 % CER % CER 30% 30% +24% 20% 20% +12% +9% +10% +10% +9% +9% +7% +7% +7% +7% +8% +8% +7% +8% +8% +9% +7% 10% +6% +4% 10% +4
Slide 6: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio Significant milestones achieved in Q3 to enable future growth +5% YTD Sep 2024 sales Diagnostics: +8% base business growth (CHFbn, YoY CER growth) (+8%)* Significant launches upcoming Itovebi: US approval in 1L PIK3CA-mut HR+ BC 10.7 Tecentriq Hybreza: US ap
Slide 7: Young portfolio to drive growth in the near- to mid-term
Young portfolio to drive growth in the near- to mid-term 2024 NME update: US approval for Itovebi (inavolisib) in HR+ breast cancer and PiaSky in PNH achieved CHFm % of Pharma Sales2 20.0 56% 18.0 50% 16.0 42% 14.0 12.0 34% 10.0 8.0 1 6.0 4.0 2.0 0.0 YTD Sep 2021 YTD Sep 2022 YTD Sep 2023 YTD Sep 20
Slide 8: A solid base to deliver future growth
A solid base to deliver future growth Pipeline and business development to add significant upside potential illustrative Business development • BD to accelerate pipeline portfolio • In-house pipeline with upside Pharma pipeline potential • On-market Pharma portfolio to deliver growth until 2027 Sale
Slide 9: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 10: R&D Excellence: Our solutions
R&D Excellence: Our solutions We identified six solutions to achieve top quartile performance - with implementation ongoing Adopt a unified portfolio Transform our portfolio Access the best external framework management & governance innovation Introduce the ‘Bar’ to recognize assets Reconfigure end-
Slide 11: 'Fast-track' of selected programs
‘Fast-track’ of selected programs Initial set of assets designated for acceleration based on exceptional potential Asset Acceleration Examples of potential acceleration levers: anti-TL1A Expediting enrollment with additional clinical trial Ph III Inflammatory Bowel Disease1 sites Trontinemab Ph III
Slide 12: Embracing bold objectives: Our 2030 R&D ambitions
Embracing bold objectives: Our 2030 R&D ambitions Toward top quartile industry performance Increase average peak year sales of Increase Ph 0 initiations/yr1: Increase Ph III success rate: pipeline assets: +50% +22%p +50% Success Volume Value rate Effectiveness R&D Excellence Costs Cycle time Efficie
Slide 13: Meaningful improvements achieved in 2024
Meaningful improvements achieved in 2024 R&D Excellence enables us to reallocate resources to new projects, new deals & accelerate priority assets Added 5 assets trough high-value CHF +0.24bn average peak year sales per Recent team-assessed PTS for partnerships and 8 assets from project trough termi
Slide 14: Pharma pipeline evolution since Pharma Day 2023
Pharma pipeline evolution since Pharma Day 2023 Since Pharma Day 2023 17 NMEs were added and 26 NMEs removed, resulting in a higher impact portfolio Pipeline changes since Q2’23 siRNA targeting AGT in hypertension 8 -8 17 Additions 81 4 -3 1 • 8 Ph I/Ph II NMEs acquired as -5 3 -4 2 part of high val
Slide 15: Pipeline acceleration through partnering and acquisitions
Pipeline acceleration through partnering and acquisitions Key deals completed to complement our pipeline across the Pharma focus therapeutic areas *pending deal closure; CVRM=cardiovascular, renal & metabolism; siRNA=small interfering RNA; AGT=angiotensinogen; TL1A=Tumor necrosis factor-like cytokin
Slide 16: Leveraging AI to increase overall Pharma productivity
Data & AI Leveraging AI to increase overall Pharma productivity Selected AI use cases along the value chain Regulatory & Manufacturing Drug development Commercialization reimbursement & distribution gRED’s ‘Lab-in-a-loop’ Document writing Digital twin Predictive alerts • AI/ML: Computational • Gen A
Slide 17: Group performance, Strategy & refocusing, Outlook
Group performance Strategy & refocusing Outlook
Slide 18: Peak sales potential of key pipeline assets (NMEs and LEs)
Peak sales potential of key pipeline assets (NMEs and LEs) New Molecular Entities (NME) giredestrant prasinezumab astegolimab HR+ BC Parkinson's disease COPD inavolisib fenebrutinib ASO Factor B • 7+ NMEs with CHF >3bn peak Pi3Km BC RMS, PPMS IgAN sales potential per asset divarasib Elevidys1 vamiki
Slide 19: 2025: Significant key newsflow ahead
2025: Significant key newsflow ahead* Compound Indication Milestone inavolisib + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval Lunsumio SC 3L+ FL US/EU approval Elevidys DMD EU approval Gazyva Lupus nephritis US/EU filing; US approval Regulatory
Slide 20: Doing now what patients need next
Doing now what patients need next
Roche Holding — Kepler Cheuvreux Virtual CEO/CFO Tour 2024 on 6ix